Zutig 50 Injection contains Tigecycline 50 mg, a broad-spectrum glycylcycline antibiotic indicated for the treatment of complicated skin and soft tissue infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia caused by susceptible strains of microorganisms. Tigecycline acts by inhibiting bacterial protein synthesis through binding to the 30S ribosomal subunit, thereby preventing the incorporation of amino acid residues into elongating peptide chains. This mechanism confers activity against a wide range of Gram-positive, Gram-negative, aerobic, and anaerobic pathogens, including multidrug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. Zutig 50 Injection is administered intravenously, with dosing adjusted based on the severity of infection and patient-specific factors such as renal or hepatic function. It is contraindicated in patients with known hypersensitivity to tigecycline or tetracycline-class antibiotics. Common adverse effects include nausea, vomiting, and infusion site reactions, while serious adverse events may involve hepatotoxicity and pancreatitis. Due to its broad-spectrum activity and unique mechanism, Zutig 50 Injection is a valuable therapeutic option in managing complex infections where resistance limits the efficacy of other antibiotics. Clinical use should be guided by susceptibility testing and local antimicrobial stewardship protocols.